{"filing":{"accession_number":"0001193805-26-000703","cik":"0001280776","ticker":"IMUX","company_name":"IMMUNIC, INC.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"e665514_8k-immunic.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/e665514_8k-immunic.htm"},"events":[{"id":8462,"run_id":7427,"accession_number":"0001193805-26-000703","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"Immunic disclosed presentation of late-breaking and additional clinical trial data from its phase 2 CALLIPER trial for vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the CMSC Annual Meeting. While this represents material clinical trial progress for a lead asset, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specific event types). The disclosure of significant clinical trial data advancement at a major medical conference is material to investors assessing the company's pipeline progress and regulatory pathway.","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2360,"accession_number":"0001193805-26-000703","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Immunic disclosed presentation of late-breaking and additional clinical trial data from its phase 2 CALLIPER trial for vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the CMSC Annual Meeting. While this represents material clinical trial progress for a lead asset, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specific event types). The disclosure of significant clinical trial data advancement at a major medical conference is material to investors assessing the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:40:24.832028+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2360,"accession_number":"0001193805-26-000703","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Immunic disclosed presentation of late-breaking and additional clinical trial data from its phase 2 CALLIPER trial for vidofludimus calcium (IMU-838) in progressive multiple sclerosis at the CMSC Annual Meeting. While this represents material clinical trial progress for a lead asset, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specific event types). The disclosure of significant clinical trial data advancement at a major medical conference is material to investors assessing the company's pipeline progress and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:40:24.832028+00:00","company_name":"IMMUNIC, INC.","ticker":"IMUX","filing_date":"2026-05-28"}]}